SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mylan Laboratories Ltd (MATRIXLABS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524794 NSE: MATRIXLABS Pharmaceuticals & Drugs | Small Cap | Mylan Laboratories Share Price

BSE Share Price
Not Listed

Mylan Laboratories Ltd (MATRIXLABS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524794 NSE: MATRIXLABS Pharmaceuticals & Drugs | Small Cap | Mylan Laboratories Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹3,273 Cr.
Current Price
₹0
52-Week Low / High
₹209 / 211
TTM EPS
₹11.6
TTM Sales
₹12,239 Cr.
Book Value per Share
₹56.7
P/E Ratio
18.02
Industry PE
49.2
Price to Book (P/B)
3.69
Price to Sales (P/S)
0.27
EV/EBITDA
4.65
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
-18.58%
Return on Capital Employed (ROCE)
-5.48%
Return on Assets (ROA)
-7.55%
Operating Profit Margin
-3.5%
Net Profit Margin
-13.26%
Gross Profit Margin
-4.7%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-25.9%
Operating Profit Growth (1 Year)
-
-118.36%
Net Profit Growth (1 Year)
-
-334.9%
Asset Quality
Promoter Holding
100.00%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹855 Cr.
Equity
₹31.3 Cr.
Face Value
₹2
All Time Low / High
₹0.42 / 312.80

Mylan Laboratories stock performance

Key Ratios
mw4me loader

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 2.8%1.3%3.1%3%8.2%11.2%7%4.9%7.9%-5.5%-
Value Creation
Index
-0.8-0.9-0.8-0.8-0.4NANANANANA-

Growth Parameters

Sales 9,4679,6239,63810,96912,23912,95811,54310,7149,7127,19612,239
Sales YoY Gr.-1.6%0.2%13.8%11.6%5.9%-10.9%-7.2%-9.4%-25.9%-
Adj EPS -13.3-27.4-24.6-22.32.834.917.213.917.2-39.111.6
YoY Gr.-NANANANA1147.1%-50.8%-19%23.8%-326.8%-
BVPS (₹) 280.3333.2316294.7289.9352.7375.2390.5230.1191.856.7
Adj Net
Profit
-323-667-598-54268.1850418339420-951182
Cash Flow from Ops. 2561,6052,1011,3251,6863,2903,0302,0612,1071,160-
Debt/CF from Ops. 42.85.84.16.54.921.721.83-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales -3%-10.1%-14.6%-25.9%
Adj EPS NA-269.4%-231.5%-326.8%
BVPS-4.1%-7.9%-20.1%-16.7%
Share Price - - - -

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-5.6-8.9-7.6-7.3110.94.73.65.6-18.59.4
Op. Profit
Mgn %
13.315.3191618.619.714.814.515.2-3.520.1
Net Profit
Mgn %
-3.4-6.9-6.2-4.90.66.63.63.24.3-13.21.5
Debt to
Equity
1.61.11.11.21.20.80.60.40.70.8-
Working Cap
Days
3603643593443293213493643594200
Cash Conv.
Cycle
1621992011871921972142232172400

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales9,467.289,622.849,637.9910,969.0412,238.5712,958.2611,543.2210,713.529,711.727,196.20
Operating Expenses + 8,216.438,198.297,806.279,231.399,972.3610,458.749,921.789,177.778,281.207,458.78
Manufacturing Costs1,547.131,542.601,327.531,731.091,690.701,708.631,887.662,121.59868.30873.38
Material Costs4,741.474,746.714,477.785,549.356,107.306,230.205,591.584,535.844,892.374,185.64
Employee Cost 809.971,007.961,064.381,106.041,195.461,433.261,471.441,577.881,414.451,480.26
Other Costs 1,117.86901.02936.58844.92978.901,086.65971.09942.461,106.08919.50
Operating Profit 1,250.851,424.551,831.731,737.652,266.212,499.521,621.441,535.761,430.52-262.58
Operating Profit Margin (%) 13.2%14.8%19.0%15.8%18.5%19.3%14.0%14.3%14.7%-3.6%
Other Income + 349.98476.26500.20308.79246.78479.93457.74241.5249.98307.36
Exceptional Items 0000000000
Interest 716.46856.94816.97827.76849.91744.26550.82239.03413.08379.08
Depreciation 1,190.801,681.191,805.901,567.231,244.571,262.871,053.961,092.76576525.39
Profit Before Tax -306.42-637.32-290.94-348.54418.50972.32474.39445.49491.42-859.69
Tax -171.67-167.7739.9459.73236.88-140-168.45-34.8285.1794.60
Profit After Tax -134.75-469.55-330.89-408.27181.621,112.31642.83480.31406.25-954.29
PAT Margin (%) -1.4%-4.9%-3.4%-3.7%1.5%8.6%5.6%4.5%4.2%-13.3%
Adjusted EPS (₹)-5.5-19.3-13.6-16.87.545.726.419.716.7-39.2
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Valuation of Mylan Laboratories - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 6,825.338,112.637,694.537,175.087,059.688,588.209,137.179,509.345,602.844,670.10
Share Capital 48.7048.7048.7048.7048.7048.7048.7048.7048.7048.70
Reserves 6,776.638,063.937,645.837,126.377,010.988,539.509,088.479,460.635,554.144,621.40
Debt +10,638.568,939.718,268.438,471.558,240.806,6645,126.264,077.893,729.283,356.38
Long Term Debt10,1988,738.668,268.438,471.558,240.805,940.214,178.903,1533,729.283,356.38
Short Term Debt440.56201.05000723.79947.36924.8900
Minority Interest0000000000
Trade Payables1,815.391,578.112,043.912,371.702,069.762,318.332,025.962,703.712,156.322,513.14
Others Liabilities 2,809.211,523.561,388.451,143.582,034.511,481.871,230.311,250.331,080.482,171.94
Total Liabilities 22,088.5020,154.0119,395.3319,161.9119,404.7619,052.3917,519.7017,541.2612,568.9112,711.57

Fixed Assets

Net Fixed Assets +10,809.0410,137.789,075.867,947.807,837.107,277.486,343.646,186.193,462.093,723.02
Gross Block13,726.8614,727.0515,371.2415,780.6916,582.0817,327.6117,532.3018,421.5810,602.6611,319.24
Accumulated Depreciation2,917.824,589.276,295.397,832.898,744.9810,050.1311,188.6612,235.397,140.577,596.22
CWIP 804.67762.06366.53328.27434.62369.07609.12525.94712.41663.14
Investments 0.230.230.230.230.230.230.230.2300
Inventories3,759.333,477.253,815.904,735.744,439.144,537.974,910.115,421.953,309.774,720.37
Trade Receivables3,126.333,603.753,607.043,669.755,083.775,012.983,914.853,945.163,6312,438.84
Cash Equivalents 383.74173.7788.7084.10179.5867.0538.905.18126.2326.64
Others Assets 3,205.151,999.182,441.092,396.031,430.321,787.621,702.861,456.631,327.421,139.57
Total Assets 22,088.5020,154.0119,395.3319,161.9119,404.7619,052.3917,519.7017,541.2612,568.9112,711.57

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 256.181,605.092,101.051,324.661,685.963,290.303,029.982,061.332,1071,160.03
PBT -306.42-637.32-290.94-348.54418.50972.32474.39445.49491.42-859.69
Adjustment 1,925.292,777.572,202.642,585.052,573.111,922.271,678.341,495.221,527.41757.35
Changes in Working Capital -1338.35-511.81213.64-902-1300.38423.98905125.27109.641254.39
Tax Paid -24.33-23.35-24.29-9.85-5.27-28.26-27.74-4.64-21.467.99
Cash Flow From Investing Activity + -5,793.96-568.66-632.12-372.15-421.19-764.05-840.95-659.94-1,015.12-637.31
Capex -716.32-931.92-511.28-358.36-497.50-906.39-857.38-906.47-1,020.33-635.66
Net Investments -47.64272.370000000-2.78
Others -5,03090.89-120.84-13.7976.31142.3416.43246.535.211.13
Cash Flow From Financing Activity + 5,574.30-966.63-1,553.71-960.36-1,118.32-2,638.74-2,217.03-1,433.78-815.70-625.12
Net Proceeds from Shares 2,476.88000000000
Net Proceeds from Borrowing 0204.3800000-921.81757.200
Interest Paid -702.07-935.10-918.28-935.02-955.98-878.97-702.12-469.60-604.61-579.56
Dividend Paid 0000000000
Others 3,799.50-235.92-635.43-25.34-162.35-1,759.77-1,514.91-42.37-968.28-45.56
Net Cash Flow 36.5269.79-84.77-7.85146.45-112.48-27.99-32.39276.18-102.39

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-2.37-6.29-4.19-5.492.5514.227.255.155.38-18.58
ROCE (%)2.781.253.132.998.1711.246.954.927.89-5.48
Asset Turnover Ratio0.50.460.490.570.630.670.630.610.650.57
PAT to CFO Conversion(x)N/AN/AN/AN/A9.282.964.714.295.19N/A
Working Capital Days
Receivable Days101.10127.60136.50121.10130.50142.20141.20133.90142.40153.90
Inventory Days132.80137.20138.10142.30136.80126.40149.40176164.10203.70
Payable Days132.90130.50147.60145.20132.70128.50141.80190.30181.30203.60

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Mylan Laboratories Ltd FAQs

The current trading price of Mylan Laboratories on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Mylan Laboratories stood at ₹3,273 Cr

The latest P/E ratio of Mylan Laboratories as of 31-Dec-1969 is 18.02.

The latest P/B ratio of Mylan Laboratories as of 31-Dec-1969 is 3.69.

The 52-week high of Mylan Laboratories is ₹211.0 and the 52-week low is ₹208.8.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Mylan Laboratories is ₹12,239 ( Cr.) .

Data is not available for this company.

No data found

No data found

About Mylan Laboratories Ltd

Matrix Laboratories (MLL), incorporated in the year 1985, is a subsidiary of US based company Mylan Inc. It is engaged in manufacturing of Active Pharmaceutical Ingredients (APIs) and Solid Oral Dosage Forms.

MLL has manufacturing facilities located in four locations in Hyderabad and Visakhapatnam, here it manufactures wide range of APIs. The company also has solid oral dosage forms facility located in Nashik. All its manufacturing plants are approved by US FDA, EDQM -EU, TGA (Australia) and has also received ISO-9000, ISO 14000 certifications. One of the core business activities of MLL is research and development of new APIs. It also offers contract research and development services for earlier stages of development and contract manufacturing for projects that have advanced further into development and are being considered for commercial manufacturing.

Mylan Inc had acquired 71.5% stake in Matrix Laboratories in 2007 for USD 736 million. Since then, the US firm has successfully integrated the two organisations, along with the generics business of Merck KGaA, to build a global, high quality pharmaceutical platform with $5.5 billion revenues in 2010.

Products

Matrix Laboratories is one of the world’s largest manufacturers and suppliers of active pharmaceutical ingredients (APIs) for a wide range of therapeutic categories, including antibacterials, central nervous system agents, antihistamine/anti-asthmatics, cardiovasculars, antivirals, antidiabetics, antifungals, proton pump inhibitors and pain management drugs.

Milestones

August 2009 - Matrix becomes a privately held Mylan subsidiary

June 2009 - Mylan announces successful Matrix delisting offer

January 2007 - Mylan Laboratories acquires a 71.5% controlling interest in Matrix Laboratories Limited

January 2007 - Matrix receives “Fastest Wealth Creator' award in Motilal Oswal Wealth Creation Study for 2006

May 2006 - Matrix receives “Best Management” award from the government of Andhra Pradesh

December 2005 - Matrix receives 'Fastest Wealth Creator' award in Motilal Oswal Wealth Creation Study for 2005

December 2005 - Matrix announces decision to acquire controlling stake in Concord Biotech, an Ahmedabad-based biotechnology company with fermentation and bio-catalytic technology capabilities and U.S. Food and Drug Administration (FDA) approved API manufacturing facilities

November 2005 - Matrix receives the National Award for R&D Efforts in Industry for 2005 in Pharmaceuticals/Chemical Sector from the Department of Scientific & Industrial Research, Government of India, Ministry of Science and Technology

June 2005 - Matrix Laboratories Limited acquires a controlling stake in Docpharma, based in Belgium

April 2005 - Matrix and Aspen Pharmacare Holdings Limited form joint ventures in India and South Africa

February 2005 - Matrix announces strategic alliance with MCHEM Pharma Group of China

January 2005 - Matrix receives 'Fastest Wealth Creator' award in Motilal Oswal Wealth Creation Study for 2004

January 2005 - Matrix purchases finished dosage facility located near Nashik, about 150 km from Mumbai

April 2004 - Matrix signs definitive agreements with India Newbridge Investments Limited and Maxwell (Mauritius) Pte. Limited

March 2004 - Matrix’s Board of Directors approves the company’s merger with Vera Laboratories Limited, Fine Drugs and Chemicals Limited, Medikon Laboratories Limited and Calibre Engineering Private Limited

March 2004 - Matrix receives U.S. FDA approval for its manufacturing facility at Jeedimetla, near Hyderabad

November 2003 - Matrix sets up two 50:50 joint venture companies, one in India and the other in Ireland

October 2003 - Matrix signs an agreement with the William J. Clinton Foundation to supply ARVs for the treatment of HIV/AIDS patients in sub-Saharan Africa, South Africa and the Caribbean countries

May 2003 - Matrix merges with Vorin Laboratories Limited and Medicorp Technologies India Limited

April 2003 - Matrix successfully files process patent applications for four products at the Indian Patent Office

Awards

In the year 2006 the company received “Best Management Award” from the Government of Andhra Pradesh

It received National Award for R&D Efforts in Industry in Pharmaceuticals /Chemical Sector from the Department of Scientific & Industrial Research, Government of India, Ministry of Science and Technology in 2005.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: